Monday, 28 September 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Financial Results · Q4 FY26

Lincoln Pharmaceuticals Q4 FY26 Results: Net Profit ₹11.6 Cr, Up 0.0% YoY

Lincoln Pharmaceuticals Ltd reported revenue from operations of ₹187.3 Cr (+11.4% YoY) and net profit of ₹11.6 Cr (+0.0% YoY) for Q4 FY26.

Q4 FY26 at a glance · ₹ crore
MetricQ4 FY26Q3 FY26Q4 FY25
Revenue from operations187.3166.3168.2
Other income-4.215.1-6.9
Total income183.1181.5161.3
Profit before exceptional items & tax16.734.716.2
Profit before tax16.734.716.2
Net profit11.628.611.6
Operating margin9.1%19.1%10.0%

A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.

Growth
Net profit, year on year+0.00%
Net profit, quarter on quarter-59.40%
Revenue, year on year+11.40%
Source

BSE results filing, NSE: LINCOLN. Figures extracted from the filing.

Read the filing ↗

Lincoln Pharmaceuticals Ltd: key numbers

Share price
₹591.00
Market cap
₹1,184 Cr
Revenue (annual)
₹671.0 Cr
Net profit (annual)
₹87.89 Cr
P/E (TTM)
12.3×Sector 50.4×
Promoter holding
49.78%+0.00% QoQ
FII holding
4.60%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Lincoln Pharmaceuticals Ltd

All →
14:08 IST BSE
Management Change

Lincoln Pharmaceuticals Management Change

Lincoln Pharmaceuticals announced the resignation of Mr. Manoj Rai, Sr. General Manager (Head QA), a Senior Management Personnel. He departs effective 24 September 2026 for personal reasons.

19:01 IST BSE
Other Announcement

Lincoln Pharmaceuticals Other Announcement

Lincoln Pharmaceuticals has dispatched physical letters to shareholders with unregistered email IDs to provide access to the Annual Report for FY 2025-26 and facilitate KYC updates.

18:49 IST BSE
Annual Report

Lincoln Pharmaceuticals Annual Report

Lincoln Pharmaceuticals submitted its Annual Report for FY 2025-26 and notice for the 32nd Annual General Meeting scheduled for September 30, 2026.